Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
Effect of 2-HOBA in Persistent Immune Activation in Long COVID POTS
NCT07189936 · View on ClinicalTrials.gov ↗
Study Summary
Long COVID is defined by a range of symptoms affecting multiple organs that persist for more than three months following an acute SARS-CoV-2 infection. Approximately 7% of individuals who recover from SARS-Cov-2 infection develop Long COVID. Long COVID Postural Orthostatic Tachycardia Syndrome (LCPOTS) symptoms include fatigue, exercise intolerance, orthostatic intolerance, syncope, and heightened orthostatic tachycardia. Research has found that decreased parasympathetic activity in LCPOTS increases the production of highly immunogenic neoantigens Isolevuglandins (IsoLG-adducts). IsoLG-adducts induce formation of circulating monocyte/T cell complexes(doublets) leading to the persistent and unresolved immune response that continues after the initial infection. The purpose of the this research, is to study the effects of 2-hydroxybenzylamine (2-HOBA), an Iso-LG-adduct scavenger, its effects in immune markers and compare it with Placebo
Conditions Studied
Interventions
- DRUG To Measure levels of circulating monocyte/ T cell doublets at Baseline
- DRUG To measure levels of circulating monocyte/ T cell doublets after 28 days of 2 HOBA treatment
- DRUG To measure levels of circulating monocyte/ T cell doublets after 28 days of Placebo treatment
- DIAGNOSTIC_TEST To Measure Splanchnic venous capacitance after 28 days of Treatment with 2HOBA
- DIAGNOSTIC_TEST To Measure Splanchnic venous capacitance after 28 days of Treatment with Placebo
Study Locations (1)
Tennessee
- Cyndya Shibao — Nashville
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 50 participants |
| Start Date | 2025-12-18 |
| Est. Completion | 2029-06-30 |
| Phase | Phase 2 |
Interested in This Trial?
Always speak with your doctor before enrolling in a clinical trial.
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT07189936
The ClinicalTrials.gov registry entry for NCT07189936 describes a study currently listed as recruiting. It is categorized as Phase 2, which is the standard way researchers label where a study sits along the investigational pathway from early safety work through later efficacy and post-marketing evaluation. The registered enrollment target is 50 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Vanderbilt University Medical Center, which has 695 total studies on file at ClinicalTrials.gov, and sponsors are the parties responsible for study design, oversight, and regulatory filings.
The record links to 4 conditions, with Post-Acute COVID-19 Syndrome appearing as the primary indexed condition, and to 5 interventions — of which To Measure levels of circulating monocyte/ T cell doublets at Baseline is the first listed. Interventions can include drugs, devices, procedures, behavioral programs, or observational arms, and each is tracked as a separate registry field so that downstream queries can filter accurately. When a trial lists multiple interventions, it usually reflects a multi-arm design or a comparison protocol rather than a single treatment being tested in isolation. The brief summary published in the registry is the clearest source of protocol intent and should be read before drawing conclusions from any sidebar tags.
Geographic footprint matters for practical reasons: NCT07189936 reports 1 study location spanning 1 distinct geographic area — top geographies include Tennessee. A larger site network tends to correlate with broader recruitment capacity, but it does not imply anything about study quality, and site-level enrollment status can diverge from the overall registry status shown above. Every data point on this page comes from the public ClinicalTrials.gov dataset and is reproduced here for reference only; it is not a medical recommendation, an endorsement of the sponsor, or an invitation to enroll. Verify current status, eligibility criteria, and contact details directly at ClinicalTrials.gov, and discuss any participation decision with your own healthcare provider.
Frequently Asked Questions
What is clinical trial NCT07189936 about?
NCT07189936 is a clinical study titled "Effect of 2-HOBA in Persistent Immune Activation in Long COVID POTS". Long COVID is defined by a range of symptoms affecting multiple organs that persist for more than three months following an acute SARS-CoV-2 infection. Approximately 7% of individuals who recover from SARS-Cov-2 infection develop Long COVID. Long COVID Postural Orthostatic Tachycardia Syndrome (LCP...
What is the current status of trial NCT07189936?
This trial is currently recruiting. It is a Phase 2 study. The enrollment target is 50 participants. The study started on 2025-12-18. Estimated completion is 2029-06-30.
What conditions does trial NCT07189936 study?
This clinical trial studies the following conditions: Post-Acute COVID-19 Syndrome, SARS CoV 2 Infection, Postural Tachycardia Syndrome (POTS), Long COVID19. These conditions were identified from the trial registry and reflect the primary focus areas of the research.
What interventions are being tested in trial NCT07189936?
The interventions under investigation include: To Measure levels of circulating monocyte/ T cell doublets at Baseline (DRUG), To measure levels of circulating monocyte/ T cell doublets after 28 days of 2 HOBA treatment (DRUG), To measure levels of circulating monocyte/ T cell doublets after 28 days of Placebo treatment (DRUG), To Measure Splanchnic venous capacitance after 28 days of Treatment with 2HOBA (DIAGNOSTIC_TEST), To Measure Splanchnic venous capacitance after 28 days of Treatment with Placebo (DIAGNOSTIC_TEST). Each intervention is being evaluated for safety and efficacy as part of this clinical study.
Who is sponsoring clinical trial NCT07189936?
This trial is sponsored by Vanderbilt University Medical Center, which has 695 total clinical trials registered on ClinicalTrials.gov. The sponsor is responsible for the study's design, funding, and regulatory compliance.
Where is trial NCT07189936 being conducted?
This trial has 1 study location across Tennessee. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
How Clinical Trials Work
Understand phases 1-4, trial design, randomization, and the informed consent process.
Patient Rights in Clinical Trials
Your rights as a participant: consent, withdrawal, privacy, and who to contact.
Finding the Right Clinical Trial
A practical guide to searching trials, understanding eligibility, and evaluating options.
All Guides
Browse our complete library of clinical trial educational resources.
Read our methodology — how this data is sourced, computed, and verified.